Wall Street Analysts Think Haemonetics (HAE) Could Surge 33.2%: Read This Before Placing a Bet

Core Viewpoint - Haemonetics (HAE) shows potential for significant upside, with a mean price target of $112.17 indicating a 33.2% upside from its current price of $84.21 [3][4]. Price Targets - The average price target consists of six estimates ranging from a low of $94 to a high of $125, with a standard deviation of $10.87, suggesting a moderate agreement among analysts [4]. - The lowest estimate indicates an 11.6% increase, while the highest suggests a 48.4% upside [4]. Analyst Sentiment - Analysts have recently shown increased optimism regarding HAE's earnings prospects, with a strong consensus on higher EPS estimates, which correlates with potential stock price increases [6][12]. - The Zacks Consensus Estimate for the current year has increased by 0.4% due to one upward revision and no negative revisions in the last 30 days [13]. Zacks Rank - HAE holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for near-term upside [14].